Published online before print June 10, 2002, doi: 10.1161/01.HYP.0000022063.50739.60
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:41.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease
From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology "L. Condorelli," Catania University (A.C., L.S.M.), Italy.
Correspondence to Prof Carmine Zoccali, Director, Centro di Fisiologia Clinica e, Divisione di Nefrologia, Via Sbarre Inferiori 39, 89131 Reggio Calabria, Italy. E-mail carmine.zoccali{at}tin.it
We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles (P=0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) (P=0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46%) than in the second (38%) and first (25%) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent (P
0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors (P=0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD.
Key Words: cardiovascular risk • dialysis • left ventricular hypertrophy • norepinephrine • renal failure • sympathetic activity • uremia
This article has been cited by other articles:
 |
|
 |
|
  G. Tripepi, F. Mattace-Raso, F. Mallamaci, F. A. Benedetto, J. Witteman, L. Malatino, and C. Zoccali Biomarkers of Left Atrial Volume: A Longitudinal Study in Patients With End Stage Renal Disease Hypertension, October 1, 2009; 54(4): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Chan Heart rate variability in patients with end-stage renal disease: an emerging predictive tool for sudden cardiac death? Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3061 - 3062. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, J. Xu, P. Wang, H. Velazquez, Y. Li, Y. Wu, and G. V. Desir Catecholamines Regulate the Activity, Secretion, and Synthesis of Renalase Circulation, March 11, 2008; 117(10): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, F. Mallamaci, F. A. Benedetto, G. Tripepi, P. Pizzini, S. Cutrupi, and L. Malatino Urotensin II and Cardiomyopathy in End-Stage Renal Disease Hypertension, February 1, 2008; 51(2): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Peterson, T. de Backer, A. Gabriel, V. Ilic, T. Vagaonescu, L. J. Appel, G. Contreras, C. Kendrick, S. Rostand, R. A. Phillips, et al. Prevalence and Correlates of Left Ventricular Hypertrophy in the African American Study of Kidney Disease Cohort Study Hypertension, December 1, 2007; 50(6): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Blankestijn SYMPATHETIC HYPERACTIVITY--A HIDDEN ENEMY IN CHRONIC KIDNEY DISEASE PATIENTS Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S293 - S297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neumann, G. Ligtenberg, I. H.T. Klein, P. Boer, P. L. Oey, H. A. Koomans, and P. J. Blankestijn Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment Hypertension, March 1, 2007; 49(3): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Blankestijn Sympathetic hyperactivity in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1354 - 1357. [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mallamaci, G. Tripepi, R. Maas, L. Malatino, R. Boger, and C. Zoccali Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, F. Mallamaci, and G. Tripepi Novel Cardiovascular Risk Factors in End-Stage Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S77 - 80. [Abstract] [Full Text]
|
|
|
|
|
|
G. de Simone Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, F. Mallamaci, G. Tripepi, F. A. Benedetto, S. Parlongo, S. Cutrupi, D. Iellamo, G. Bonanno, F. Rapisarda, P. Fatuzzo, et al. Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2611 - 2617. [Abstract] [Full Text] [PDF]
|
|